Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

Jimmy L. Zhao, Emmanuel S. Antonarakis, Heather H. Cheng, Daniel J. George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D. Schonhoft, Amanda Anderson, Ninghui Mao, Samuel Haywood, Brooke K. Decker, Tracy Curley, Wassim Abida, Felix Y. Feng, Karen E. Knudsen, Brett S. Carver, Mario E. Lacouture, Alexander W. Wyatt, Dana E. Rathkopf